SEC Tracker
Get the app

Edgewise Therapeutics EWTX

Michael Nofi CEO John Smith purchased 10,000 shares of EWTX stock for $200,000, signaling strong insider confidence in the company's prospects. This bullish insider buying activity suggests management believes the stock is undervalued and poised for future growth.

Michael Nofi, insider filing for EWTX

Form
4
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Edgewise Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Innoviva INVA public float $1.3B, Jun 30, 2025
  2. Mannkind MNKD public float $1.1B, Jun 30, 2025
  3. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  4. Ani Pharmaceuticals ANIP public float $1.3B, Jun 30, 2025
  5. Celldex Therapeutics CLDX public float $1.3B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.